Guidance

MenB vaccine (Bexsero®): patient group direction template

PGD template to support the national meningococcal group B (Bexsero®) vaccination programme and public health management of meningococcal disease.

Documents

MenB vaccine (Bexsero®): patient group direction (PGD) template

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of MenB vaccine to individuals from 8 weeks of age eligible for the national routine meningococcal group B vaccination programme and to individuals for the prevention of secondary cases of meningococcal group B disease in accordance with the Guidance for the public health management of meningococcal disease in the UK.

It is valid from 1 May 2018 to 30 April 2020.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012. Practitioners should follow local policy and procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.

Published 14 August 2015
Last updated 11 May 2018 + show all updates
  1. Template revised to align with the new Guidance for the Public Health Management of Meningococcal Disease in the UK.
  2. Updated dosing recommendations for individuals with incomplete vaccination status, and revision to allow administration of booster dose in the left thigh.
  3. First published.